Artefenomel: a promising new antimalarial drug

The Lancet Infectious Diseases

Volumn 16, Issue 1, 2016, Pages 6-8

  Rosenthal, Philip J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEFENOMEL; ARTEMISININ; DIHYDROARTEMISININ PLUS PIPERAQUINE; ADAMANTANE; ANTIMALARIAL AGENT; PEROXIDE;

CHEMOPROPHYLAXIS; DRUG ABSORPTION; DRUG COST; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; HEMOLYSIS; HUMAN; MALARIA; MALARIA CONTROL; MEDICATION COMPLIANCE; NOTE; PARASITE CLEARANCE; PARASITEMIA; PHARMACOPHORE; PREGNANCY; PRIORITY JOURNAL; PROPHYLAXIS; ANALOGS AND DERIVATIVES; FEMALE; MALARIA, FALCIPARUM; MALARIA, VIVAX; MALE;

ADAMANTANE; ANTIMALARIALS; FEMALE; HUMANS; MALARIA, FALCIPARUM; MALARIA, VIVAX; MALE; PEROXIDES;

EID: 85027947965     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(15)00343-6     Document Type: Note

References (14)

1. Charman, SA, Arbe-Barnes, S, Bathurst, IC, et al. Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria. Proc Natl Acad Sci USA 108 (2011), 4400–4405.
2. Phyo, AP, Jittamala, P, Nosten, FH, et al. Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with Plasmodium falciparum and Plasmodium vivax malaria: an open-label phase 2 trial. Lancet Infect Dis, 2015 published online Oct 5. http://dx.doi.org/10.1016/S1473-3099(15)00320-5.
3. Ashley, EA, Dhorda, M, Fairhurst, RM, et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 371 (2014), 411–423.
4. Rosenthal, PJ, The interplay between drug resistance and fitness in malaria parasites. Mol Microbiol 89 (2013), 1025–1038.
5. Chaorattanakawee, S, Saunders, DL, Sea, D, et al. Ex vivo drug susceptibility testing and molecular profiling of clinical Plasmodium falciparum isolates from Cambodia from 2008 to 2013 suggest emerging piperaquine resistance. Antimicrob Agents Chemother 59 (2015), 4631–4643.
6. Leang, R, Taylor, WR, Bouth, DM, et al. Evidence of Plasmodium falciparum malaria multidrug resistance to artemisinin and piperaquine in western Cambodia: dihydroartemisinin-piperaquine open-label multicenter clinical assessment. Antimicrob Agents Chemother 59 (2015), 4719–4726.
7. Paddon, CJ, Westfall, PJ, Pitera, DJ, et al. High-level semi-synthetic production of the potent antimalarial artemisinin. Nature 496 (2013), 528–532.
8. Dong, Y, Chollet, J, Matile, H, et al. Spiro and dispiro-1,2,4-trioxolanes as antimalarial peroxides: charting a workable structure-activity relationship using simple prototypes. J Med Chem 48 (2005), 4953–4961.
9. Wang, X, Dong, Y, Wittlin, S, et al. Comparative antimalarial activities and ADME profiles of ozonides (1,2,4-trioxolanes) OZ277, OZ439, and their 1,2-dioxolane, 1,2,4-trioxane, and 1,2,4,5-tetraoxane isosteres. J Med Chem 56 (2013), 2547–2555.
10. Moehrle, JJ, Duparc, S, Siethoff, C, et al. First-in-man safety and pharmacokinetics of synthetic ozonide OZ439 demonstrates an improved exposure profile relative to other peroxide antimalarials. Br J Clin Pharmacol 75 (2013), 524–537.
11. Valecha, N, Looareesuwan, S, Martensson, A, et al. Arterolane, a new synthetic trioxolane for treatment of uncomplicated Plasmodium falciparum malaria: a phase II, multicenter, randomized, dose-finding clinical trial. Clin Infect Dis 51 (2010), 684–691.
12. Ades, V, Safety, pharmacokinetics and efficacy of artemisinins in pregnancy. Infect Dis Rep, 3, 2011, e8.
13. Jaureguiberry, S, Thellier, M, Ndour, PA, et al. Delayed-onset hemolytic anemia in patients with travel-associated severe malaria treated with artesunate, France, 2011–2013. Emerg Infect Dis 21 (2015), 804–812.
14. Delves, M, Plouffe, D, Scheurer, C, et al. The activities of current antimalarial drugs on the life cycle stages of Plasmodium: a comparative study with human and rodent parasites. PLoS Med, 9, 2012, e1001169.